Main
tumorsAdebrelimab
Neoadjuvant chemoradiotherapy (nCRT) followed by esophagectomy offered a 23% absolute benefit of long-term survival over 10 years (46% versus 23% with surgery alone, Neoadjuvant immunotherapy is promising because of its therapeutic efficacy across a variety of solid tumorsAdebrelimab is a high-affinity, humanized monoclonal antibody against PD-L1, which has been demonstrated to be effective and safe in advanced ESCC